Once-weekly insulin efsitora alfa versus once-daily insulin . . . Efsitora showed non-inferior HbA1c reductions and similar rates of combined clinically significant or severe hypoglycaemia versus glargine U100 in participants with type 2 diabetes treated with basal and prandial insulin These findings show that efsitora is a well tolerated and efficacious once-weekly alternative to daily basal insulin, with a reduced injection frequency, for the treatment of
People with Severe Type 1 Diabetes are Cured in Small Trial . . . "A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of Type 1 diabetes," reports the New York Times "One year later, these 10 patients no longer need insulin The other two patients need much lower doses " The experimental treatment, cal